A daily compilation of articles, manuscripts, and news focused on the ADC market and compiled for the scientists who are making the cure everyday.
Thursday, May 16, 2019
Mechanism on patients who dont respond to Kadcyla
Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancerinduces ROR1 and confers resistance through activation of Hippotranscriptional coactivator YAP1
This is a pretty interesting paper trying to identify why some patients don't respond to T-DM1 based therapy. After demonstrating an increased expression of ROR1 resulting from T-DM1 administration, they demonstrate that inhibiting ROR1 could be a potential treatment for these patients.
Pretty cool stuff.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment